首页> 外文OA文献 >Analysis of Adenovirus-Host Interactions to Improve Recombinant Adenoviral Vectors for Gene Therapy
【2h】

Analysis of Adenovirus-Host Interactions to Improve Recombinant Adenoviral Vectors for Gene Therapy

机译:腺病毒宿主相互作用分析改善基因治疗重组腺病毒载体

摘要

Recombinant adenoviral vectors are among the most commonly used vehicles in gene therapy. Replication-deficient adenoviruses include early generation adenoviruses, which are deleted in less than three adenoviral genes, and the high-capacity adenoviruses (HC-AdV) as the most advanced form. HC-AdVs are deleted for all viral sequences leaving only the two inverted terminal repeat sequences (ITRs) and the packaging signal from the original viral genome. Therefore, up to 36 kilobases of foreign DNA can be packaged by HC-AdV particles and transduced into the desired target cell. Efficacy of these vectors was shown in several animal models, in which a single injected virus dose resulted in up to 3 years of transgene expression. However, also for recombinant adenoviruses including HC-AdVs limiting factors remain, which were investigated and improved in the course of this work.The production of HC-AdV represents one limiting factor because it is a labour intensive and sophisticated process that requires some experience. Therefore, in this study, a protocol was developed that simplifies the generation of these viruses starting with an improved cloning procedure and ending with precise titration of the purified particles. In addition, this improved virus production procedure was used to demonstrate the feasibility of HC-AdV to delivery short-hairpin RNAs, thus reducing hepatitis B RNA molecules in vitro and in vivo.The majority of HC-AdVs are currently based on the adenovirus serotype 5 (Ad5). However, DNA sequences inserted into the HC-AdV genome and remaining viral sequences were shown to influence duration and stability of transgene expression, which can negatively influence the outcome of a therapeutic approach. By analyzing viral ITR sequences derived from different adenoviral serotypes, this work demonstrated that ITR-driven transcriptional activity from several serotypes but also inhibiting functions occur leading to reduced transgene expression. Furthermore, a negative impact of ITR sequences on nearby promoters could be observed. The data obtained in this work suggest that it could be beneficial to introduce shielding sequences into the HC-AdV genome, which flank the transgene expression cassettes and therefore, prevent undesired side effects. Moreover, the results indicated, that pursuing ITRs from adenovirus serotype 7 in the context of an adenoviral vector could be advantageous, as it demonstrated most suitable features regarding transcriptional activation and influence on promoter performance.The efficiency of HC-AdV in terms of long-term expression of foreign DNA sequences is mainly based on the stability of vector genomes in quiescent cells. In dividing cells, however, a continuous reduction of the viral DNA reduces the therapeutic effect. Thus, integration systems on the basis of viral hybrid vectors were developed, which result into recombinase-mediated somatic integration of the therapeutic DNA from the HC-AdV genome into the chromosomal DNA. The most prominent representative of non-viral integration systems is the Sleeping Beauty (SB) transposase. Although function and efficacy of this transposase was shown in the context of an HC-AdV, it turned out, that transgene expression is decreased after Sleeping Beauty mediated transposition. Herein, analysis of transposition in cells with suppressed RNA interference pathway, showed a higher transposition rate in RNA interference knockdown cells compared to control cells, which was mainly based on an increased transgene expression. Therefore, this work shows for the first time that due to convergent transcription, originated from the two SB recognition sequences (IRs) flanking the transposon, formation of double-stranded RNAs (dsRNAs) can occur. These dsRNAs can be substrates for the RNAi mechanism and contribute to the silencing of gene expression. In the future this finding can be used to significantly improve the SB transposon technology.Moreover the influence of the RNAi mechanism on the adenovirus life cycle could be demonstrated within this project. By the suppression of the RNAi pathway using an RNAi suppressor protein we could improve recombinant adenovirus replication and viral particle production, up to 100-fold. In addition, this RNAi suppressor protein increased production of HC-AdV up to 6-fold. This upregulation was mainly based on the increased expression of viral regulatory proteins as well as the suppression of small adenoviral RNAs.In conclusion, this work provides different strategies to improve HC-AdVs for gene therapeutic purposes. Furthermore, it investigated mechanisms that negatively interfere with the therapeutic outcome, which need to be considered in future work. In particular, the influence of the RNA interference pathway on the replication profile of recombinant adenoviruses could be demonstrated for the first time essentially broadening the potential of these vectors with respect to viral production and design of oncolytic adenoviruses. In summary, this study emphasizes the importance of understanding the biology of viral vectors systems, which then can be translated into the development of optimized vectors for gene therapeutic applications.
机译:重组腺病毒载体是基因治疗中最常用的载体。复制缺陷型腺病毒包括早期的腺病毒,它们在少于三个的腺病毒基因中被删除,高容量的腺病毒(HC-AdV)是最先进的形式。删除所有病毒序列的HC-AdV,仅留下两个反向末端重复序列(ITR)和原始病毒基因组的包装信号。因此,HC-AdV颗粒可以包装多达36千个碱基的外源DNA,并转导到所需的靶细胞中。这些载体的功效已在几种动物模型中显示,其中单次注射病毒剂量可导致长达3年的转基因表达。但是,对于包含HC-AdVs的重组腺病毒,仍然存在限制因素,在这项工作过程中已对其进行了研究和改进。HC-AdV的生产是一个限制因素,因为它是一项劳动密集型且复杂的过程,需要一些经验。因此,在这项研究中,开发了一种协议,该协议从改进的克隆程序开始,以精确滴定纯化的颗粒结束,从而简化了这些病毒的产生。此外,这种改进的病毒生产程序用于证明HC-AdV传递短发夹RNA的可行性,从而减少了体内和体外的乙型肝炎RNA分子。目前大多数HC-AdV都基于腺病毒血清型5(Ad5)。但是,已显示插入HC-AdV基因组的DNA序列和剩余的病毒序列会影响转基因表达的持续时间和稳定性,这可能会对治疗方法的结果产生负面影响。通过分析衍生自不同腺病毒血清型的病毒ITR序列,这项工作证明了ITR驱动的几种血清型的转录活性,但也存在抑制功能,导致转基因表达降低。此外,可以观察到ITR序列对附近启动子的负面影响。这项工作中获得的数据表明,将屏蔽序列引入HC-AdV基因组可能是有益的,该序列位于转基因表达盒的侧面,因此可以防止不良的副作用。而且,结果表明,在腺病毒载体的背景下从腺病毒血清型7中寻求ITR可能是有利的,因为它证明了有关转录激活和对启动子性能的影响的最合适的特征。外来DNA序列的术语表达主要基于静止细胞中载体基因组的稳定性。然而,在分裂细胞中,病毒DNA的连续减少会降低治疗效果。因此,开发了基于病毒杂交载体的整合系统,其导致重组酶介导的治疗性DNA从HC-AdV基因组到体细胞DNA的体细胞整合。非病毒整合系统最杰出的代表是“睡美人”(SB)转座酶。尽管在HC-AdV的背景下显示了该转座酶的功能和功效,但事实证明,在“睡美人”介导的转座后,转基因表达降低。在本文中,具有抑制的RNA干扰途径的细胞中的转座分析显示,与对照细胞相比,RNA干扰敲除细胞中的转座率更高,这主要是基于转基因表达的增加。因此,这项工作首次表明,归因于转录转座子两侧的两个SB识别序列(IR)的聚合转录,可能会形成双链RNA(dsRNA)。这些dsRNA可能是RNAi机制的底物,并有助于基因表达的沉默。将来,这一发现可用于显着改善SB转座子技术。此外,RNAi机制对腺病毒生命周期的影响可以在该项目中得到证明。通过使用RNAi抑制蛋白抑制RNAi途径,我们可以将重组腺病毒复制和病毒颗粒产生提高100倍。此外,这种RNAi抑制蛋白使HC-AdV的产量增加了6倍。这种上调主要基于病毒调节蛋白的表达增加以及对小腺病毒RNA的抑制。总之,这项工作提供了不同的策略来改善用于基因治疗的HC-AdVs。此外,它研究了对治疗结果产生负面影响的机制,这在以后的工作中需要加以考虑。特别是,首次证明了RNA干扰途径对重组腺病毒复制谱的影响,从而从本质上拓宽了这些载体在病毒生产和溶瘤腺病毒设计方面的潜力。总而言之,这项研究强调了了解病毒载体系统生物学的重要性,然后可以将其转化为用于基因治疗应用的优化载体的开发。

著录项

  • 作者

    Rauschhuber Christina;

  • 作者单位
  • 年度 2011
  • 总页数
  • 原文格式 PDF
  • 正文语种 {"code":"en","name":"English","id":9}
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号